Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
Saved in:
| Title: | Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. |
|---|---|
| Authors: | Rediti M; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium., Fernandez-Martinez A; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Venet D; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium., Rothé F; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium., Hoadley KA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Parker JS; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Singh B; White Plains Hospital, White Plains, NY, USA., Campbell JD; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA., Ballman KV; Alliance Statistics and Data Management Center, Weill Cornell Medicine, New York, NY, USA., Hillman DW; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA., Winer EP; Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA., El-Abed S; Breast International Group, Brussels, Belgium., Piccart M; Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium., Di Cosimo S; Integrated biology platform unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Symmans WF; Department of Pathology, University of Texas, MD Anderson Cancer Center, Houston, TX, 77030, USA., Krop IE; Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA., Salgado R; Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Loi S; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Pusztai L; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA., Perou CM; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Carey LA; Division of Hematology-Oncology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Sotiriou C; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium. christos.sotiriou@hubruxelles.be. |
| Source: | Nature communications [Nat Commun] 2023 Nov 03; Vol. 14 (1), pp. 7053. Date of Electronic Publication: 2023 Nov 03. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-023-42635-2 |
